Larimar Therapeutics price target raised to $12 from $11 at Wedbush

Core Viewpoint - Wedbush has raised the price target for Larimar Therapeutics (LRMR) to $12 from $11 while maintaining an Outperform rating on the shares, indicating positive sentiment towards the company's future performance [1]. Group 1: Financial Developments - Larimar Therapeutics completed an upsized $100 million offering after receiving Breakthrough Therapy designation for nomlabofusp in Friedreich's ataxia, which is a significant milestone for the company [1]. - Following the capital raise, Wedbush is increasing its Q4 spending forecast to align with year-end 2025 cash projections of $137 million [1]. Group 2: Regulatory Environment - Despite recent FDA decisions causing investor concern, Wedbush remains optimistic as Larimar continues to engage in active dialogue with the agency, suggesting a proactive approach to regulatory challenges [1].